IBI3002
IBI3002 is a pharmaceutical drug with 5 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
Clinical Trials (5)
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5